* If you want to update the article please login/register
Background: The E-26 transformation-specific related gene is often present in cytogenetically normal acute myeloid leukemia. Herein, we did a meta-analysis to see if there was a correlation between the prognostic significance of ERG expression and CN-AML. From seven published studies, a total of 667 CN-AML patients were identified. 429 had poor ERG, and 238 had high levels of ERG among the 667 patients undergoing chemotherapy, with 429 showing no signs of ERG, and 238 had high expression of ERG. Using fixed- or random-effects models, the ERG expression and CN-AML's confidence interval and the 95% confidence interval were estimated for the ERG expression and CN-AML. Overall, patients with high ERG expression had a greater chance of relapse and reduced complete remission. Both internal tandem duplications of the fms-related tyrosine kinase 3 gene and brain, as well as acute leukemia, were identified with the ERG expression. Conclusion: In CN-AML, a high ERG expression could be used as a significant adverse prognostic factor.
Source link: https://doi.org/10.4103/0366-6999.207474
Patients with RUNX1 mutations have a dismal prognosis with anthracycline/cytarabine-based chemotherapy. In order to determine the presence of residual disease in this molecular disease subset, we aimed to create an in vivo model of RUNX1-mutated, CN-AML. Within 6 weeks, Tail vein injection of CG-SH into NOD scid gamma mice resulted in leukemic engraftment in the bone marrow, spleen, and peripheral blood. We conclude that the CG-SH xenografts are a robust, reproducible in vivo model of CN-AML in which to investigate chemotherapy resistance mechanisms and novel therapeutic strategies.
Source link: https://doi.org/10.1371/journal.pone.0132375
About half of adult AML is caused by Cytogenetically normal acute myeloid leukemias. Given the role of genomic instability in leukemogenesis, expression analysis of DNA repair genes may help to sharpen prognosis determination in CN-AML. A publicly available gene expression profile from two independent cohorts of patients with CN-AML was examined. We investigated the prognostic value of 175 genes involved in DNA repair. Both training and validation cohorts were based on three risk groups with varying clinical outcomes. Our GE-based DNA repair score may be used as a biomarker to determine patient with CN-AML outcomes, as well as NPM1 and FLT3 mutation status. The ability to identify CN-AML patients whose tumor cells are dependent on specific DNA repair pathways to introduce new therapeutic avenues has the ability to determine CN-AML patients whose tumor cells are dependent on specific DNA repair pathways in order to identify new therapeutic avenues.
Source link: https://doi.org/10.3390/cancers12102874
P 1. 0001, n = 232], as well as in the European LeukemiaNet Intermediate Risk AML group, a non-M3 AML group, and the non-M3 AML group — all survival and event-free survival. Conclusion: We also showed that CLIC4 is a novel, unfavorable prognosticator, and therapeutic goal for CN-AML by furthering WGCNA on multi-omics results.
Source link: https://doi.org/10.3389/fonc.2020.01648
However, the clinical relevance and biological significance of TET1 expression in cytogenetically normal acute myeloid leukemia is uncertain. As a result, elevated TET1 expression was more prevalent in M0/M1 morphology and genes of NPM1 mutations, as well as underrepresented in CEBPA double allele mutations in our AML patients. In particular hub oncogenes, expression of several hub oncogenes appears to be limited by some miRNAs like miR-127-5p, miR-21, and miR-616 in high TET1 expressers, according to mRNA and miRNA integrative tests. In conclusion, the TET1 gene expression may be a good predictor of patients with AML.
Source link: https://doi.org/10.1016/j.ebiom.2018.01.031
Abstract Background LncRNAs can control miRNAs and mRNAs by sequestering and binding them. However, the roles of ceRNA in acute myeloid leukemia, particularly in pediatric and adolescent AML, were not fully understood. Materials and methods 27 cytogenically normal acute leukemia patients under 18 years old with matching clinical results were selected from the cancer genome atlas, which was a large sample sequencing database of RNA sequencing. Results We gathered survival specific lncRNAs, miRNAs, and mRNAs, as well as a weighted correlation network of CN-AML patients and a weighted correlation network. Moreover, we discovered 4 biological pathways related to OS and selected the most enriched pathway, u2018Transcriptional misregulation in cancer, to show that it can accurately predict younger CN-AML patients u2019 prognosis and guide treatment. Conclusions We established a life-long ceRNA network, which may be a new approach to lncRNA research in younger CN-AML.
Source link: https://doi.org/10.1186/s12935-018-0621-0
The most diverse and heterogeneous AML subgroup is Cytogenetically normal acute myeloid leukemia. This paper explored the relationship between microRNA expression and prognostic outcomes for CN-AML, based on the RNA/microRNA sequencing results of CN-AML patients. CN-AML's expression and low miR-188-5p expression were found to be highly associated with longer overall survival and event-free survival, whether alone or in a mixed manner. Many common microRNA signatures indicating promising results in previous experiments were up-regulated in both high let-7-3p expressers and low miR-188-5p expressers, including miR-35a, miR-335, and miR-125b, as well as all members of the miR-181 family, indicating positive results in previous studies. We concluded that high let-7a-2-3p and low miR-188-5p expression could be used as favorably prognostic biomarkers either alone or in a combination fashion in CN-AML patients, whether they had HSCT or not.
Source link: https://doi.org/10.1371/journal.pone.0118099
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions